Eli Lilly and Co LLY 0.26% shares are plunging nearly 8.0 percent in early trading on Monday after the company announced that it is discontinuing development of cardiovascular disease treatment drug evacetrapib because of disappointing efficacy. Here’s a look at what shareholders can expect and which companies benefit most from the decision.

What Now?

According to the company, Eli Lilly shareholders should expect a $90 million Q4 charge amounting to about five cents per share as a result of the decision to drop evacetrapib. The decision came after an independent data monitoring committee reviewed late-stage trial data on the drug and found insufficient efficacy and low probability that the study would hit its primary target.

Company Disappointed

Company insiders are…

Click here to continue reading

Want to learn more about how to profit off the stock market? Or maybe you just want to be able to look sophisticated in front of your coworkers when they ask you what you are reading on your Kindle, and you’d prefer to tell them “Oh, I’m just reading a book about stock market analysis,” rather than the usual “Oh, I’m just looking at pics of my ex-girlfriend on Facebook.” For these reasons and more, check out my book, Beating Wall Street with Common Sense. I don’t have a degree in finance; I have a degree in neuroscience. You don’t have to predict what stocks will do if you can predict what traders will do and be one step ahead of them. I made a 400% return in the stock market over five years using only basic principles of psychology and common sense. Beating Wall Street with Common Sense is now available on Amazon, and tradingcommonsense.com is always available on your local internet!